Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
February 18 2014 - 8:25AM
Marketwired
Rosetta Genomics Appoints Kevin Watson as Director,
Reimbursement-Managed Care
Recognized Expert in Healthcare Policy and Reimbursement to Lead
Payer Efforts for Company's Line of microRNA Diagnostics
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Feb 18, 2014)
- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics, announces the
appointment of Kevin Watson to the newly established role of
Director, Reimbursement-Managed Care. Mr. Watson is a seasoned
reimbursement specialist with nearly 25 years of experience in
healthcare policy and reimbursement, managed care marketing, and
new product development and commercialization.
"We are delighted to welcome Kevin to the Rosetta team to drive
our reimbursement and managed care strategy and
initiatives. Reimbursement is critical for commercial success
and, as 2014 is a year of commercial execution for Rosetta, this is
a timely and important hire for us," stated Kenneth A. Berlin,
President and Chief Executive Officer of Rosetta Genomics. "Kevin's
experience devising strategic marketing, growth, and operational
plans directed to the payer, integrated health system, hospital and
distributor channels will be an invaluable asset for Rosetta as we
execute our commercial plans for our current suite of cancer
testing services and plan for the launch of future microRNA-based
diagnostics."
Mr. Watson joins Rosetta
Genomics from competing molecular diagnostics company,
bioTheranostics, where for two years he was the Director of
Reimbursement. Prior to this, Mr. Watson was the President of
GlobalPayer, a payer relations and reimbursement consulting and
outsourcing company serving providers and manufacturers in the
medical device and diagnostic industry. Mr. Watson was the
Regional Marketing/Payer Relations Director at Becton Dickinson
Diagnostics - TriPath Imaging for 6 years, where he was responsible
for the development, execution and management of reimbursement
outcomes with large payer organizations, Medicare and
Medicaid. Previous to that, Mr. Watson held positions as
Executive Director, Business Development at LabCorp., and Network
Product Development Leader, Executive Director with Quest
Diagnostics, Inc. Mr. Watson started his career in payer management
at Aetna Health Plans, where he spent four years as Administrator,
National Vendor Contracting.
"This is an exciting time to be
joining Rosetta to develop and manage the Company's payer relations
strategy," said Kevin Watson. "Rosetta's cancer testing services
provide critical and objective diagnostic data that may help
physicians to select optimal treatment options and improve patient
outcomes. I am looking forward to working with the Rosetta
team as we build and expand the Company's microRNA diagnostic
product offerings to bring truly personalized medicine to
patients."
About Rosetta Cancer Testing
Services Rosetta Cancer Tests are a series of microRNA-based
diagnostic testing services offered by Rosetta Genomics. The
Rosetta Cancer Origin Test™ can accurately identify the primary
tumor type in primary and metastatic cancer including cancer of
unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™
diagnoses mesothelioma, a cancer connected to asbestos
exposure. The Rosetta Lung Cancer Test™ accurately identifies
the four main subtypes of lung cancer using small amounts of tumor
cells. The Rosetta Kidney Cancer Test™ accurately classifies the
four most common kidney tumors: clear cell renal cell carcinoma
(RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta's assays are designed to provide objective
diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S.
alone, Rosetta Genomics estimates that 200,000 patients a year may
benefit from the Rosetta Cancer Origin Test™, 60,000 from the
Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer
Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The
Company's assays are offered directly by Rosetta Genomics in the
U.S., and through distributors around the world. For more
information, please visit www.rosettagenomics.com. Parties
interested in ordering the test can contact Rosetta Genomics at
(215) 382-9000 ext.
309.
About Rosetta Genomics Rosetta develops and commercializes a
full range of microRNA-based molecular diagnostics. Founded in
2000, Rosetta's integrative research platform combining
bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human
microRNAs. Building on its strong patent position and proprietary
platform technologies, Rosetta is working on the application of
these technologies in the development and commercialization of a
full range of microRNA-based diagnostic tools. Rosetta's cancer
testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost
& Sullivan recognized Rosetta Genomics with the 2012 North
American Next Generation Diagnostics Entrepreneurial Company of the
Year Award.
Forward-Looking Statement Disclaimer Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test™, Rosetta's development or commercialization of molecular
diagnostics, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test™, Rosetta's
development of personalized medicine products and services, the
reproducibility, robustness and accuracy of Rosetta's microRNA
technology and its ability to help enable personalized medicine and
optimize treatment, the expansion of payor coverage of Rosetta's
testing services, and the amount of people covered for the Rosetta
testing services, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including those risks more
fully discussed in the "Risk Factors" section of Rosetta's Annual
Report on Form 20-F for the year ended December 31, 2012 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
Company Contact: Rosetta Genomics Ken Berlin President & CEO
(609) 419-9003
investors@rosettagenomics.com Investor Contacts: LHA Anne Marie
Fields (212) 838-3777
afields@lhai.com or Bruce Voss (310) 691-7100
bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024